Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells

Experimental and Molecular Pathology

Volumn 97, Issue 1, 2014, Pages 44-48

  Green, Taryn L ^a   Santos, Mark F ^a   Ejaeidi, Ahmed A ^a   Craft, Barbara S ^a   Lewis, Robert E ^a   Cruse, Julius M ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Circulating tumor cells; Metastatic breast carcinoma; Toll like receptor

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN P 15095; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 8;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL POPULATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LONG TERM SURVIVAL; METASTASIS POTENTIAL; PERIPHERAL CIRCULATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR IMMUNITY;

CIRCULATING TUMOR CELLS; METASTATIC BREAST CARCINOMA; TOLL-LIKE RECEPTOR;

BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; NEOPLASTIC CELLS, CIRCULATING; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTORS;

EID: 84901380727     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.05.003     Document Type: Article

References (53)

1. Agrawal S., Agrawal A., Doughty B., Gerwitz A., Blenis J., Van Dyke T., Pulendran B. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 2003, 171:4984-4989.
2. Alemar J., Schuur E.R. Progress in using circulating tumor cell information to improve metastatic breast cancer therapy. J. Oncol. 2013, 2013:702732. 10.1155/2013/702732.
3. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738. 10.1038/35099560.
4. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F.J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J.-P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., André F., Delaloge S., Tursz T., Kroemer G., Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059. 10.1038/nm1622.
5. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Frees K., Watt J.L., Schwartz D.A. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 2000, 25:187-191. 10.1038/76048.
6. Basith S., Manavalan B., Yoo T.H., Kim S.G., Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch. Pharm. Res. 2012, 35:1297-1316. 10.1007/s12272-012-0802-7.
7. Bidard F.-C., Mathiot C., Delaloge S., Brain E., Giachetti S., de Cremoux P., Marty M., Pierga J.-Y. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann. Oncol. 2010, 21:729-733. 10.1093/annonc/mdp391.
8. Cottalorda A., Verschelde C., Marçais A., Tomkowiak M., Musette P., Uematsu S., Akira S., Marvel J., Bonnefoy-Berard N. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur. J. Immunol. 2006, 36:1684-1693. 10.1002/eji.200636181.
9. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W.M.M., Hayes D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351:781-791. 10.1056/NEJMoa040766.
10. Fabbri M., Paone A., Calore F., Galli R., Gaudio E., Santhanam R., Lovat F., Fadda P., Mao C., Nuovo G.J., Zanesi N., Crawford M., Ozer G.H., Wernicke D., Alder H., Caligiuri M.A., Nana-Sinkam P., Perrotti D., Croce C.M. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. PNAS 2012, 109:12278-12279. 10.1073/pnas.1209414109.
11. Fehm T., Becker S., Duerr-Stoerzer S., Sotlar K., Mueller V., Wallwiener D., Lane N., Solomayer E., Uhr J. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007, 9:R74. 10.1186/bcr1783.
12. Ferrantini M., Capone I., Belardelli F. Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev. 2008, 19:93-107. 10.1016/j.cytogfr.2007.10.003.
13. Fukata M., Hernandez Y., Conduah D., Cohen J., Chen A., Breglio K., Goo T., Hsu D., Xu R., Abreu M.T. Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm. Bowel Dis. 2009, 15:997-1006. 10.1002/ibd.20880.
14. González L.O., Pidal I., Junquera S., Corte M.D., Vázquez J., Rodríguez J.C., Lamelas M.L., Merino A.M., García-Muñiz J.L., Vizoso F.J. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br. J. Cancer 2007, 97:957-963. 10.1038/sj.bjc.6603963.
15. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002, 111:927-930.
16. Green T.L., Craft B.S., Cruse J.M., Lewis R.E. Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp. Mol. Pathol. 2013, 95:174-179.
17. He W., Liu Q., Wang L., Chen W., Li N., Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol. Immunol. 2007, 44:2850-2859. 10.1016/j.molimm.2007.01.022.
18. Huang B., Zhao J., Shen S., Li H., He K.-L., Shen G.-X., Mayer L., Unkeless J., Li D., Yuan Y., Zhang G.-M., Xiong H., Feng Z.-H. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res. 2007, 67:4346-4352. 10.1158/0008-5472.CAN-06-4067.
19. Huang Y., Cai B., Xu M., Qiu Z., Tao Y., Zhang Y., Wang J., Xu Y., Zhou Y., Yang J., Han X., Gao Q. Gene silencing of Toll-like receptor 2 inhibits proliferation of human liver cancer cells and secretion of inflammatory cytokines. PLoS ONE 2012, 7:e38890. 10.1371/journal.pone.0038890.
20. Ignatiadis M., Rothé F., Chaboteaux C., Durbecq V., Rouas G., Criscitiello C., Metallo J., Kheddoumi N., Singhal S.K., Michiels S., Veys I., Rossari J., Larsimont D., Carly B., Pestrin M., Bessi S., Buxant F., Liebens F., Piccart M., Sotiriou C. HER2-positive circulating tumor cells in breast cancer. PLoS ONE 2011, 6:e15624. 10.1371/journal.pone.0015624.
21. Inoue J.-I., Gohda J., Akiyama T., Semba K. NF-kappaB activation in development and progression of cancer. Cancer Sci. 2007, 98:268-274. 10.1111/j.1349-7006.2007.00389.x.
22. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995. 10.1038/ni1112.
23. Jing Y.-Y., Han Z.-P., Sun K., Zhang S.-S., Hou J., Liu Y., Li R., Gao L., Zhao X., Zhao Q.-D., Wu M.-C., Wei L.-X. Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med. 2012, 10:98. 10.1186/1741-7015-10-98.
24. Karikó K., Ni H., Capodici J., Lamphier M., Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 2004, 279:12542-12550. 10.1074/jbc.M310175200.
25. Karin M., Lawrence T., Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-835. 10.1016/j.cell.2006.02.016.
26. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384. 10.1038/ni.1863.
27. Kim S., Takahashi H., Lin W.-W., Descargues P., Grivennikov S., Kim Y., Luo J.-L., Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106. 10.1038/nature07623.
28. Kluwe J., Mencin A., Schwabe R.F. Toll-like receptors, wound healing, and carcinogenesis. J. Mol. Med. 2009, 87:125-138. 10.1007/s00109-008-0426-z.
29. Li X., Jiang S., Tapping R.I. Toll-like receptor signaling in cell proliferation and survival. Cytokine 2010, 49:1-9. 10.1016/j.cyto.2009.08.010.
30. Lianidou E.S., Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin. Chem. 2011, 57:1242-1255. 10.1373/clinchem.2011.165068.
31. Liu H., Komai-Koma M., Xu D., Liew F.Y. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7048-7053. 10.1073/pnas.0601554103.
32. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444. 10.1038/nature07205.
33. Murdoch C., Giannoudis A., Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234. 10.1182/blood-2004-03-1109.
34. Nadal R., Fernandez A., Sanchez-Rovira P., Salido M., Rodríguez M., García-Puche J.L., Macià M., Corominas J.M., Delgado-Rodriguez M., Gonzalez L., Albanell J., Fernández M., Solé F., Lorente J.A., Serrano M.J. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012, 14:R71. 10.1186/bcr3180.
35. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036. 10.1126/science.1078231.
36. Pestrin M., Bessi S., Galardi F., Truglia M., Biggeri A., Biagioni C., Cappadona S., Biganzoli L., Giannini A., Di Leo A. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 2009, 118:523-530. 10.1007/s10549-009-0461-7.
37. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediat. Inflamm. 2010, 2010. 10.1155/2010/672395.
38. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466. 10.1038/nature02924.
39. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
40. Riethdorf S., Müller V., Zhang L., Rau T., Loibl S., Komor M., Roller M., Huober J., Fehm T., Schrader I., Hilfrich J., Holms F., Tesch H., Eidtmann H., Untch M., von Minckwitz G., Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 2010, 16:2634-2645. 10.1158/1078-0432.CCR-09-2042.
41. Salaun B., Coste I., Rissoan M.-C., Lebecque S.J., Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 2006, 176:4894-4901.
42. Sato Y., Goto Y., Narita N., Hoon D.S.B. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2009, 2(Suppl. 1):205-214. 10.1007/s12307-009-0022-y.
43. Simiantonaki N., Kurzik-Dumke U., Karyofylli G., Jayasinghe C., Michel-Schmidt R., Kirkpatrick C.J. Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. Int. J. Mol. Med. 2007, 20:21-29.
44. Su X., Ye J., Hsueh E.C., Zhang Y., Hoft D.F., Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 2010, 184:1630-1641. 10.4049/jimmunol.0902813.
45. Swaby R.F., Cristofanilli M. Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med. 2011, 9:43. 10.1186/1741-7015-9-43.
46. Switzer C.H., Glynn S.A., Cheng R.Y.-S., Ridnour L.A., Green J.E., Ambs S., Wink D.A. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol. Cancer Res. 2012, 10:1203-1215. 10.1158/1541-7786.MCR-12-0124.
47. Tibbe A.G.J., Miller M.C., Terstappen L.W.M.M. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007, 71:154-162. 10.1002/cyto.a.20369.
48. Timoshenko A.V., Lala P.K., Chakraborty C. PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. Int. J. Cancer 2004, 108:384-389. 10.1002/ijc.11575.
49. Vicari A.P., Caux C., Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 2002, 12:33-42. 10.1006/scbi.2001.0400.
50. Wang Q., Takei Y., Kobayashi O., Osada T., Watanabe S. Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells. J. Clin. Biochem. Nutr. 2009, 45:163-170. 10.3164/jcbn.09-21.
51. Xie W., Huang Y., Xie W., Guo A., Wu W. Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting toll-like receptor 2 in the cancer cells. PLoS ONE 2010, 5:e10850. 10.1371/journal.pone.0010850.
52. Xie W., Wang Y., Huang Y., Yang H., Wang J., Hu Z. Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem. Biophys. Res. Commun. 2009, 379:1027-1032. 10.1016/j.bbrc.2009.01.009.
53. Zhang L., Riethdorf S., Wu G., Wang T., Yang K., Peng G., Liu J., Pantel K. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 2012, 18:5701-5710. 10.1158/1078-0432.CCR-12-1587.